Shanghai Haohai Biological Technology Co., Ltd. (FRA:5HB)

Market Cap	1.03B -35.7%
Revenue (ttm)	301.13M -8.3%
Net Income	30.57M -40.3%
EPS	0.13 -40.0%
Shares Out	n/a
PE Ratio	33.65
Forward PE	n/a
Dividend	0.12 (4.85%)
Ex-Dividend Date	Sep 5, 2025

Volume	n/a
Average Volume	11
Open	2.500
Previous Close	2.500
Day's Range	2.480 - 2.500
52-Week Range	2.400 - 3.260
Beta	n/a
RSI	35.16
Earnings Date	Mar 20, 2026

About FRA:5HB

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel, anti-adhesion, and burn wound related products. In addition, it provides injectors, scalpels, suture needles and other products. Further, ...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 2,156
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5HB

Financial Performance

In 2025, FRA:5HB's revenue was 2.47 billion, a decrease of -7.71% compared to the previous year's 2.68 billion. Earnings were 251.01 million, a decrease of -40.30%.

Financial numbers in CNY